• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    bioAffinity Technologies, Inc. - Common Stock (NQ:BIAF)

    3.860 -0.860 (-18.22%)
    Delayed Quote Updated: 3:30 PM EDT, Oct 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about bioAffinity Technologies, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    Catalysts Emerge BIAF, LIDR, SSM, GMGMF to Watch Now
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    Algorhythm Holdings (NASDAQ: RIME) Volume Surges as Q2 Revenue Jumps 161%, Potential Oversold Setup Emerges
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    Q2 Virtual Investor Summit Presentations Now Available On Demand
    From Investor Summit Group
    Via ACCESS Newswire
    News headline image
    bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Closing of $3.2 Million Offering
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Pricing of $3.2 Million Offering
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
    From bioAffinity Technologies, Inc.
    Via Business Wire
    News headline image
    bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment
    From bioAffinity Technologies, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.